Clinical trials will most certainly first include those patients with the highest risk of relapse. However, long term, everything will depend on the risk/ benefit trade off: if an effective, simple, well-tolerated and cost-effective treatment was available (let's imagine a single short low-dose PD1 for any early Melanoma patient) that prevented progression for most patients would be very different from a highly toxic, expensive treatment that doesn't work for everyone (think Ipi 10mg/kg adjuvant)- so everything is in the trade-off